We carried out an observational study to analyze if the quality of life of T1DM patients is affected by different insulin treatment systems. The study involved 113 T1DM patients from a public diabetes center, mean age 32.61(±12.59) years, 46% male treated with MDI or CSII. The Insulin System Rating Questionnaire (IDSRQ) was validated in Brazilian Portuguese (Table 1) and was self-completed by the subjects during a routine visit. Multiple comparison analysis (Table 2) showed that CSII had a significant effect versus syringe and versus pen for treatment satisfaction and clinical efficacy domains. CSII was associated with a higher treatment satisfaction and patient’s perception of better clinical efficacy than MDI.


R.C.L. Coelho: None. A.S. Pagano: None. A.N. Soares: None. J.S. Reis: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.